Clinical Trials Browser

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT04020809 2026-03-09

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Phase 1 Active not recruiting

20 enrolled

Dermatologic

Melanoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03175432 2025-11-03

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

29 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04273061 2025-09-22

CAPTIV-8

Phase 2 Recruiting

200 enrolled

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms, Unknown Primary, Sarcoma, Skin Neoplasms, Urogenital Neoplasms

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms

NCT04356729 2025-06-29

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Phase 2 Active not recruiting

30 enrolled

Dermatologic

Melanoma

NCT02902029 2025-04-09

ImmunoCobiVem

Phase 2 Completed

186 enrolled

Dermatologic

Melanoma

NCT05483400 2025-03-30

TIRACAN

Phase 2 Recruiting

97 enrolled

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma

NCT04722575 2025-03-13

NEO-TIM

Phase 2 Active not recruiting

95 enrolled

Dermatologic

Melanoma

NCT05110781 2023-09-05

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

Phase 2 Terminated

1 enrolled 9 charts

DermatologicHead & Neck

Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown

1,800 enrolled

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT02303951 2021-02-03

NEO-VC

Phase 2 Terminated

47 enrolled

Dermatologic

Melanoma

Clinical Trials

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

CAPTIV-8

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

ImmunoCobiVem

TIRACAN

NEO-TIM

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Microbiome Immunotherapy Toxicity and Response Evaluation

NEO-VC